Developmental regulation of N-terminal H2B methylation in Drosophila melanogaster

Munich Center of Integrated Protein Science and Adolf-Butenandt Institute, Ludwig Maximilians University of Munich, 80336 Munich, Germany.
Nucleic Acids Research (Impact Factor: 9.11). 11/2011; 40(4):1536-49. DOI: 10.1093/nar/gkr935
Source: PubMed


Histone post-translational modifications play an important role in regulating chromatin structure and gene expression in vivo. Extensive studies investigated the post-translational modifications of the core histones H3 and H4 or the linker histone
H1. Much less is known on the regulation of H2A and H2B modifications. Here, we show that a major modification of H2B in Drosophila melanogaster is the methylation of the N-terminal proline, which increases during fly development. Experiments performed in cultured cells
revealed higher levels of H2B methylation when cells are dense, regardless of their cell cycle distribution. We identified
dNTMT (CG1675) as the enzyme responsible for H2B methylation. We also found that the level of N-terminal methylation is regulated
by dART8, an arginine methyltransferase that physically interacts with dNTMT and asymmetrically methylates H3R2. Our results
demonstrate the existence of a complex containing two methyltransferases enzymes, which negatively influence each other’s

Download full-text


Available from: Ignasi Forne
    • "NRMT was shown to be promiscuous and is able to methylate protein substrates other than RCC1, such as SET (also known as TAF-I or PHAPII) and the retinoblastoma protein RB [8]. An ortholog of NRMT in Drosophila melanogaster , dNTMT, was shown to catalyze methylation of histone H2B [10]. For bacteria, methylation of the ribosomal protein L11 has been relatively well characterized. "
    Dataset: FEBS CypM

    No preview · Dataset · Oct 2014
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The posttranslational methylation of N-terminal α-amino groups (α-N-methylation) is a ubiquitous reaction found in all domains of life. Although this modification usually occurs on protein substrates, recent studies have shown that it also takes place on ribosomally synthesized natural products. Here we report an investigation of the bacterial α-N-methyltransferase CypM involved in the biosynthesis of the peptide antibiotic cypemycin. We demonstrate that CypM has low substrate selectivity and methylates a variety of oligopeptides, cyclic peptides such as nisin and haloduracin, and the ε-amino group of lysine. Hence it may have potential for enzyme engineering and combinatorial biosynthesis. Bayesian phylogenetic inference of bacterial α-N-methyltransferases suggests that they have not evolved as a specific group based on the chemical transformations they catalyze, but that they have been acquired from various other methyltransferase classes during evolution.
    Preview · Article · Jul 2012 · FEBS letters
  • [Show abstract] [Hide abstract]
    ABSTRACT: Epigenetics is a major field of biomedical research, and epigenetic drug discovery shows great promise for new drugs. The first epigenetic inhibitors are already approved for human treatment. Here, we review a number of case studies that cover different aspects of epigenetic drug discovery spanning from sequencing of epigenetic modifications, assays development over screening to medicinal chemistry, in vivo testing and clinical application.
    No preview · Article · Oct 2012 · Future medicinal chemistry
Show more